NCT02359903View on ClinicalTrials.gov

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Infliximab (BCD-055)

infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha

DRUG

Infliximab (Remicade)

Trial Locations (6)

Unknown

Vitebsk Regional Clinical Hospital, Vitebsk

Chelyabinsk Regional Clinical hospital, Chelyabinsk

Research Institute of Rheumotology, Moscow

Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko, N.Novgorod

North-Western State Medical University n.a. I.I.Mechnikov, Saint Petersburg

Local hospital at the station Smolensk OAO RZD, Smolensk

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT02359903 - Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter